{"id":301448,"date":"2026-10-12T11:29:28","date_gmt":"2026-10-12T05:59:28","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=301448"},"modified":"2026-10-12T11:29:28","modified_gmt":"2026-10-12T05:59:28","slug":"lupin-best-stock-in-its-sector","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/lupin-best-stock-in-its-sector\/","title":{"rendered":"Is Lupin the Best Stock in Its Sector? A Look at the Numbers"},"content":{"rendered":"

Lupin CMP Rs 1,959 (12 Oct 2026). Market cap Rs 89,629 Cr. ROE 23.76%. P\/E 16.15x versus Industry P\/E 36.69x.<\/em><\/p>\n

\n

Quick Answer<\/strong><\/p>\n

Lupin is one of the names investors compare when screening the Healthcare sector, built on a 23.76% return on equity and a P\/E of 16.15x against an Industry P\/E of 36.69x. Whether Lupin is the best stock in its sector depends on whether an investor is optimising for return ratios, valuation, or both. This article breaks down the metrics, including a comparison against named Healthcare sector peers, so you can judge that for yourself.<\/p>\n<\/p><\/div>\n

Is Lupin<\/a> the best stock in its sector? The stock trades on the NSE at Rs 1,959 as of 12 October 2026, within its 52-week range of Rs 1,900.00 to Rs 2,529.50. Lupin Ltd, based in Mumbai, is a global pharmaceutical company that makes and sells branded and generic formulations, biotechnology products and APIs across India, the US and other markets.<\/p>\n

Lupin sits in the Healthcare sector, and its 23.76% ROE and 16.15x P\/E give a starting point for judging where it stands against comparable listed names. The rest of this article compares those numbers against verified peers and the sector’s Industry P\/E benchmark.<\/p>\n

Also read – Is Abbott India the Best Stock in Its Sector? A Look at the Numbers<\/a><\/p>\n

Click Here – Get Free Investment Predictions<\/strong><\/a><\/p>\n

\n
\n

Table of Contents<\/p>\nToggle<\/span><\/path><\/svg><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n